Manage settings
MENU
About this site
In het Nederlands
Home
Researchers
Projects
Organisations
Publications
Infrastructure
Contact
Research Explorer
Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.
Researcher
Kaat Durinck
Profile
Projects
Publications
Activities
Awards & Distinctions
Results
:
ALL
(
28
)
Order By :
Title (a-z)
Title (a-z)
Chronological by starting year (new to old)
As
Promotor-spokesperson
01 January 2022 → 31 December 2025
Replication fork protector dependency factors: novel targets for combination treatment and immunomodulation in neuroblastoma (REINFORCE)
Funding: Regional and community funding: Special Research Fund
01 January 2024 → 31 December 2027
Synergistic drug interactions with CDK12-controlled DNA damage response signaling as potential therapy for high-risk neuroblastoma
Funding: Research Foundation - Flanders (FWO)
As
Administrative supervisor
20 January 2023 → 21 September 2025
Development of patient avatars to scrutinize for customized tyrosine kinase selection and facilitate entry points for combination therapy to combat pediatric sarcoma
Doctoral researcher: Deyna Keppens
21 November 2022 → 21 September 2025
Functional evaluation of novel therapeutic targets in neuroblastoma using in vivo zebrafish modelling
Doctoral researcher: Soetkin Leys
21 February 2022 → 21 September 2025
Preclinical evaluation of combined RRM2/DNA damage response signaling as therapy for high-risk neuroblastoma and potential entry point for sensitization to immune checkpoint inhibition.
Doctoral researcher: Iris Nelen
09 September 2022 → 21 September 2025
Replication fork protector dependency factors: novel targets for combination treatment and immunomodulation in neuroblastoma
Doctoral researcher: Carolien Van Damme
19 November 2024 → 21 September 2025
Scrutinizing AURKA degradation as a novel entry point for drug synergism in rhabdomyosarcoma
Doctoral researcher: Kaat De Wever
11 October 2024 → 21 September 2025
Synergistic drug interactions with CDK12-controlled DNA damage response signaling as potential immunomodulatory therapy for high-risk neuroblastoma
Doctoral researcher: Rizwan Ahmad
As
PhD Supervisor
26 November 2024 → 21 September 2025
Doctoral project Lasse Vleminckx
Doctoral researcher: Lasse Vleminckx
20 October 2020 → 22 September 2024
Doctoral project Muhammad Rishfi
Doctoral researcher: Muhammad Rishfi
As
Promotor
01 November 2023 → 31 October 2024
Beurs Emmanuel van der Schueren (EvdS) Carolien Van Damme: "Scrutinizing the role of GJC1 as replicative stress resistor in MYCN driven neuroblastoma"
Fellow: Carolien Van Damme
Funding: Funding by bilateral agreement (private and foundations)
01 September 2021 → 31 August 2026
BOF-TT-professorship in pediatric precision oncology
Fellow: Kaat Durinck
Funding: Regional and community funding: Special Research Fund
01 January 2022 → 31 December 2025
Building a next-generation precision oncology platform for childhood cancer
Funding: Regional and community funding: Special Research Fund
25 September 2023 → 31 December 2025
Development of patient avatars in zebrafish for personalized selection of tyrosine kinase inhibitor-based combination therapy to combat relapsed pediatric sarcoma
Funding: Funding by bilateral agreement (private and foundations)
14 November 2023 → 13 November 2025
Functional assessment of TAS1553 as entry point for synergistic drug interactions with the CDC7-ATR-CHK1 axis in vitro and in vivo
Funding: Funding by bilateral agreement (private and foundations)
01 October 2023 → 30 September 2026
Preclinical evaluation of synergistic drug interactions with CDK12-controlled DNA damage response signaling as potential therapy for high-risk neuroblastoma
Funding: Funding by bilateral agreement (private and foundations)
01 October 2024 → 30 September 2027
The chromatin remodeling protein PHF6 at the crossroad between the nuclear pore complex and replicative stress responses in the childhood cancer neuroblastoma
Fellow: Lisa Depestel
Funding: Regional and community funding: Special Research Fund
01 October 2021 → 30 September 2025
The role of the SOX11 lineage-dependency factor as epigenetic master regulator in neuroblastoma
Funding: Regional and community funding: Special Research Fund
01 May 2024 → 30 April 2025
Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate students
Fellow: Joshua Robert Goulding
Funding: Regional and community funding: Special Research Fund
As
Copromotor
01 November 2020 → 31 October 2024
The dual role PSIP1 in T-cell acute lymphoblastic leukemia (T-ALL)
Fellow: Lisa Demoen
Funding: Research Foundation - Flanders (FWO)
01 October 2019 → 30 July 2024
The PHF6 - TLX1 cooperativity and the IL7R-JAK3 signaling axis as drug target in PHF6 deficient TALL.
Funding: Regional and community funding: Special Research Fund
01 May 2024 → 30 April 2028
ThirdGenT: linking third-generation sequencing of (epi)genomes, (epi)transcriptomes and translatomes to life sciences revolutionizes oncology, rare diseases, microbiology, cell and gene technology, developmental and computational biology
Funding: Research Foundation - Flanders (FWO)
As
Fellow
01 September 2021 → 31 August 2026
BOF-TT-professorship in pediatric precision oncology
Fellow: Kaat Durinck
Funding: Regional and community funding: Special Research Fund
01 October 2016 → 30 September 2019
Identification of novel therapeutic targets through multi-level (epi) genomic landscaping of replicative stress resistant neuroblastoma
Fellows: Kaat Durinck
Funding: Regional and community funding: Special Research Fund
01 January 2018 → 31 December 2018
The chromatin modifier BRD3 as a key novel player in DNA repair and vulnerable therapeutic target in neuroblastoma
Fellows: Kaat Durinck
Funding: Research Foundation - Flanders (FWO)
01 January 2015 → 31 December 2015
The PHF6 - TLX1 cooperativity and the IL7R-JAK3 signaling axis as drug target in PHF6 deficient T-ALL
Fellow: Kaat Durinck
Funding: Research Foundation - Flanders (FWO)
01 October 2018 → 31 August 2021
The role of BRCA1 as oncogenic replicative stress resistor in MYCN driven neuroblastoma
Fellow: Kaat Durinck
Funding: Research Foundation - Flanders (FWO)
01 October 2010 → 05 January 2016
Unraveling the role of PHF6 in normal T cell development and T-cell acute lymphoblastic leukemia
Fellow: Kaat Durinck
Funding: Regional and community funding: IWT/VLAIO